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https://doi.org/10.1016/j.celrep.2020.108117SUMMARYRecent advances in induced pluripotent stem cell (iPSC) technology and directed differentiation of iPSCs into
cardiomyocytes (iPSC-CMs)make it possible tomodel genetic heart disease in vitro. We apply CRISPR/Cas9
genome editing technology to introduce three RBM20 mutations in iPSCs and differentiate them into iPSC-
CMs to establish an in vitromodel of RBM20mutant dilated cardiomyopathy (DCM). In iPSC-CMs harboring a
known causal RBM20 variant, the splicing of RBM20 target genes, calcium handling, and contractility are
impaired consistent with the disease manifestation in patients. A variant (Pro633Leu) identified by exome
sequencing of patient genomes displays the same disease phenotypes, thus establishing this variant as dis-
ease causing. We find that all-trans retinoic acid upregulatesRBM20 expression and reverts the splicing, cal-
cium handling, and contractility defects in iPSC-CMs with different causal RBM20 mutations. These results
suggest that pharmacological upregulation of RBM20 expression is a promising therapeutic strategy for
DCM patients with a heterozygous mutation in RBM20.INTRODUCTION
Dilated cardiomyopathy (DCM) is characterized by enlargement
of the left ventricle and reduced systolic function (Hershberger
et al., 2010). Its incidence is estimated at 1 in 250 individuals,
making DCM a leading cause of heart failure (Yancy et al.,
2013) and the most common indication for heart transplantation
(Japp et al., 2016). Heart transplantation is indicated for patients
with end-stage DCM, but access is limited, and the procedure is
not appropriate for all patients. Despite an improvement in pa-
tient outcomes after transplantation over the past 20 years,
development of comorbidities remains a serious problem and
the 10-year survival rate is just above 50% (Lund et al., 2017).C
This is an open access article under the CC BY-N
(91) -Thirty to fifty percent of DCMcases involve inheritedmutations
located in more than 50 individual genes, including many that
affect sarcomeric proteins and contractile function (Kinnamon
et al., 2017; McNally and Mestroni, 2017; Wilcox and Hersh-
berger, 2018). These genes are thought to partially explain the
variable clinical presentation, age of disease onset, and outcome
(Hershberger et al., 2013). Patient genetics does not yet play a
major role in guiding treatment decisions for inherited DCM
(Hershberger et al., 2013). Emerging evidence, however, sup-
ports the use of genetics to identify individuals at increased
risk for disease progression, congestive heart failure, and
arrhythmia as well as for selecting therapeutic strategies (Hersh-





t'Ce =>ress Cell Reports derived from patients or harboring mutations introduced by
CRISPR genome editing offer a means to develop or select
personalized therapeutics. There exist numerous examples of
disease-relevant phenotypes that have been reproduced
in vitro using cardiomyocytes differentiated from iPSCs (iPSC-
CMs) derived from patients (Wyles et al., 2016). Here, we have
used patient iPSC-CMs as a genetic tool to provide proof-of-
concept for a mechanism-based therapeutic strategy.
Mutations in the splicing factor RBM20 cause a severe form of
inherited DCM associated with early onset, end-stage heart fail-
ure (also in younger patients) and increased incidence of sudden
death (Hey et al., 2019; Parikh et al., 2019; Streckfuss-Bömeke
et al., 2017). Disease severity is consistent with the physiological
function of RBM20 in regulating heart-specific splicing of many
genes essential for the function of cardiac muscle, many of
which are also linked to cardiac disease such as TTN, CAMK2D,
and RYR2 (Beraldi et al., 2014; Guo et al., 2012; Maatz et al.,
2014; Streckfuss-Bömeke et al., 2017; Wyles et al., 2016).
We studied a previously uncharacterized variant in RBM20
(Pro633Leu; P633L) that co-segregated with DCM and compared
it to another variant classified as disease-causing.We used iPSC-
CMs to establish that the P633L variant causes errors in mRNA
splicing and pathological contractility associated with RBM20-
deficientDCM.We identified all-trans retinoic acid (ATRA) as a po-
tential regulator of RBM20. We showed that ATRA increases
RBM20 expression and with high-throughput physiological
recording demonstrated that it ameliorates the cellular defects,
suggesting that transcriptional upregulation might be therapeuti-
cally beneficial for patients with RBM20-deficient DCM.
RESULTS
Linkage Analysis Identifies DCM-Causing Mutation in
RBM20
We identified a family with familial DCM (Figure 1A), where the
grandfather (I;3), father (II;4), and uncle (II;7) of the proband
(III;4) passed away with diagnoses of DCM at ages 74, 69, and
53, respectively. In addition, an aunt (II;6) was diagnosed with
DCM. The proband presented with a mildly dilated left ventricle
and a mildly reduced ejection fraction in 2002. The mother was
unaffected by DCM. To identify the disease-causing mutation
in this family, we performed exome sequencing on the proband,
his father (II;4), his mother (II;3), and his aunt (II;6) (Figure S1A).
We found 21,170 variants that were present in father, aunt, and
son but not in the mother. We did not find any previously re-
ported DCM-causing mutations. We then examined variants in
genes previously linked to DCM (Janin et al., 2018) (Figure S1B).
There were five variants in three genes occurring at a frequency
of less than 5% in the 1000 Genomes Project and having a
missense effect on protein sequences: TTN, LDB3, and
RBM20 (Table S1). The variants in TTN and LDB3 had been re-
ported and annotated as benign, likely benign, or as variants of
unknown significance. Independently, we performed panel
sequencing on the father (II;4) in which we targeted 95 prevalent
sudden cardiac death-related genes (Chanavat et al., 2016).
Both strategies identified a missense mutation in RBM20 adja-
cent to a known mutation hotspot in the highly evolutionarily
conserved RS domain (arginine/serine-rich domain) (Figures2 Cell Reports 32, 108117, September 8, 20201B and 1C) (Brauch et al., 2009; Li et al., 2010). The mutation
is a proline-to-leucine change at amino acid position 633
(P633L) (Figure S1C). All of the immediately following positions
in RBM20, from amino acid 634 to 638, have been previously
associated with familial DCM (Brauch et al., 2009; Guo et al.,
2012; Li et al., 2010).
To evaluate the pathogenic potential of the P633L mutation
independently of the genomic background of the patient, we
applied CRISPR/Cas9 to generate a set of isogenic iPSC lines
(Figure 1D). In an iPSC line derived from a healthy individual,
we introduced either the P633L mutation, the Arg634Gln
(R634Q) mutation, previously described as pathogenic (Brauch
et al., 2009), or a frameshift mutation at position 635 (Ser635Fra-
meShift [S635FS]) that results in the formation of a premature
stop codon and consequent loss of function consistent with a
knockout (KO) (Figures S1D–S1J) (Miller and Pearce, 2014).
Each edit resulted in homozygous mutations. One clone that un-
derwent the genome editing procedure without gaining a muta-
tion in the RBM20 gene was selected and utilized as an addi-
tional healthy control (named wild-type [WT]; in addition to the
unedited parental line, WT-NC). All the iPSC lines were differen-
tiated into iPSC-CMs via modulation of WNT signaling as previ-
ously described (Burridge et al., 2014), selected via glucose star-
vation, and then matured for 4 more weeks before each
experiment (Figure 1E) (Feyen et al., 2020).
RBM20 Mutant iPSC-CMs Exhibit Aberrant Splicing
To evaluate the impact of the P633Lmutation on RBM20-depen-
dent splicing, we performed RNA sequencing (RNA-seq) anal-
ysis on the iPSC-CMs from each genotype (Figure S2A). Alterna-
tive splicing events were inferred from the RNA-seq data using
DEXSeq with significant hits being further filtered on percent
spliced-in (PSI) calculations. All the RBM20-WT lines clustered
together, independent of whether they went through the genome
editing process (Figure 2A). All the mutant lines clustered
together. The PSI plot of CAMK2D in Figure S2B shows different
exon preference between WT and RBM20 mutant iPSC-CMs.
Aberrant splicing of TTN and RyR2 was confirmed by real-time
PCR (Figures S2C–S2F). These mis-splicing events correspond
to the mis-spliced exons previously described for DCM muta-
tions (Beraldi et al., 2014; Guo et al., 2012; Maatz et al., 2014;
Streckfuss-Bömeke et al., 2017; Wyles et al., 2016). To test for
P633L-specific splicing defects, we directly compared this line
to the R634Q and the S635FS lines. We did not find any signifi-
cant differences in the target gene sets between the mutants
despite the P633L mutation having a less severe effect on
splicing (Figure 2A). To evaluate the splicing patterns of patient
cells, we generated iPSC-CMs from the proband (DCM1) and
compared the splicing of selected RBM20 targets to the splicing
patterns of WT and S635FS iPSC-CMs. Figure 2B shows an in-
termediate splicing phenotype of the heterozygous mutant
DCM1 iPSC-CMs lying between the WT and the homozygous
S635FS for TTN and CAMK2D.
RBM20 Mutant iPSC-CMs Show Impaired Calcium and
Contractile Function
DCM patients exhibit a significant reduction in left ventricle frac-
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Figure 1. Identification of a Previously Uncharacterized Mutation in the RS Region of RBM20 in a Family with Inherited DCM
(A) Family pedigree of the proband. Square, male; circle, female; black, affected; white, unaffected; slash through the symbol, deceased; (+), mutant allele; (),
wild-type allele.
(B) Schematic representation of RBM20 protein with predicted functional domains: P-rich, proline rich; Zn finger, Zinc finger domain; RRM, RNA-recognition
motif; RS, arginine/serine-rich domain; E-rich, glutamate rich. The previously reported mutations in the RS domain are indicated. The mutation identified by this
study is shown in red text and marked with an asterisk (*).
(C) Alignment of RBM20 from human and six other vertebrates. Residues conserved between human RBM20 and these species are indicated by an asterisk (*).
(D) Schematic of genome editing strategy. ssDNA, single-stranded DNA; sgRNA, single guide RNA.
(E) Schematic of cardiomyocytes differentiation from iPSCs, annotated with the corresponding media supplementations. CHIR99021 is RPMI + B27-Ins +














- - - - - •• - - L...-fll....._____, .. ----•-•---'//-+. evaluate whether the P633L mutation causes a clinically relevant
phenotype in our system, iPSC-CMs were assayed for contrac-
tility (representative recordings forWT and the P633Lmutant can
be seen in Video S1). Contractile function was reduced in all
mutant lines, as measured by maximum displacement at systole
(Figure 2C). To evaluate the contractile function of patient cells,
we examined iPSC-CMs from the proband (DCM1) and his father
(DCM2). In both lines, contractile function was significantly
reduced (Figure 2C).
It has been proposed that a reduced calcium release from the
sarcoplasmic reticulum impairs heart contraction (Marks, 2003).
Many of the RBM20 targets are involved in calcium handling. To
test whether calcium handling was altered in RBM20 mutants,
we assayed iPSC-CMs for calcium transients (representative re-
cordings for WT and the P633L mutant can be seen in Video S1).
Calcium upstroke was significantly slower in the mutated lineswith a stronger effect in homozygous than heterozygous lines
(Figure 2D).
Retinoic Acid Upregulates RBM20 Expression and
Corrects Splicing Defects
We hypothesized that transcriptional upregulation of RBM20
could be a therapeutic strategy to compensate for loss of function
of a heterozygous mutated allele. We interrogated the Gene
Expression Atlas database (Petryszak et al., 2014) for conditions
that upregulateRBM20 and found that ATRA treatment was asso-
ciated with upregulation of RBM20 expression in human embry-
onic stem cells in a genome-wide dataset (Colleoni et al., 2011).
We confirmed that ATRA can induce upregulation of RBM20 tran-
script and protein in murine myoblast C2C12 cells (Figures 3A–
3C). ATRA treatment of C2C12 cells induced skipping of


































































































































































































































































Figure 2. In Vitro Model of RBM20-Deficient DCM Recapitulates Molecular and Cellular Defects Relevant to Pathogenesis
(A) Heatmap of PSI values for genes affected by RBM20 mutations. For TTN, the most affected exon is displayed. WT is the unedited iPSC line; WT-NC is the
parental line.
(B) qPCR results for selected RBM20-targets (CAMK2D and TTN) in WT, DCM1, and S635FS iPSC-CM (n = 6). Data are presented as mean ± SD.
(C) Time-series-based analysis of contractile profiles of RBM20 WT and mutant iPSC-CMs (n = 12). AU, arbitrary unit.
(D) Time-series-based analysis of calcium transients. Upstroke time is the calcium influx time in WT and RBM20mutant iPSC-CMs (n = 18). (n.s., non-significant;
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j i III• T D significant (Figure 3D). We thus evaluated ATRA in a more sensi-
tive RBM20-dependent TTN splicing reporter assay in HEK293
cells (Liss et al., 2018) and observed an increase in RBM20 activity
as determined by a decrease of the firefly luciferase (FLuc) signal
normalized to Renilla luciferase (RLuc) (Figure S3A). ATRA treat-
ment caused a dose-dependent reduction of the FLuc signal in
the absence of exogenous RBM20 (Figure S3A). In the presence
of exogenous RBM20, firefly luciferase was decreased only at
ATRA concentrations exceeding 0.15 mM (Figure S4A). To eval-
uate RBM20-independent effects of ATRA on the luciferase-
based splicing reporter, we tested its effect on the RBM20 inde-
pendent titin exon Mex4-6 reporter (Maatz et al., 2014). No effect
was observed on this second reporter (Figure S3B). These data
suggest that ATRA exerts its effects on splicing through RBM20.
To test the effect of ATRA on human iPSC-CMs, we treated
WT and patient-derived iPSC-CMswith ATRA. Upon ATRA treat-4 Cell Reports 32, 108117, September 8, 2020ment, we observed dose-dependent upregulation of the RBM20
transcript in all the lines (Figures 4A, S3C, and S3D). In addition,
other known ATRA targets such as GATA4, CYP26B1, RARA,
RARB,WNT5A, and BRINP2 were upregulated on the transcript
level as determined by RNA-seq (Figures S3E and S3F; Table
S2). To confirm that upregulation of RBM20 transcript levels in
iPSC-CMs was sufficient to induce upregulation of RBM20 pro-
tein, we generated a knockin mCherry tag of endogenous
RBM20 in iPSCs. We differentiated these cells into iPSC-CMs
and treated them with two different doses of ATRA. Upon 72 h
ATRA treatment, we observed a significant increase in mCherry
fluorescence (Figures S4A and S4B). To evaluate whether the
upregulation of RBM20 was sufficient to revert the splicing de-
fects, we analyzed TTN and CAMK2D splicing and observed a
moderate but consistent correction of aberrant splicing in TTN
and CAMK2D upon ATRA treatment (Figures 4B, S4C, and
A B
Figure 3. ATRA Upregulates RBM20 Expression
(A) qRT-PCR analysis of RBM20 expression in C2C12 upon treatment with
different doses of ATRA. Tubulin alpha is used as endogenous control (n = 3).
Data are presented as mean ± SD.
(B) Western blot analysis of RBM20 protein after treatment of C2C12 cells with
0.625 and 5 mM ATRA. Tubulin alpha is used as loading control.
(C) Densitometric analysis of RBM20 signal normalized to tubulin alpha signal
for the western blot in (B). Data are presented as mean ± SD.
(D) PSI of titin IG exons 241 to 243 in C2C12 at different concentrations of
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ATRA Conc [µM] ATRA Conc [µM] S4D; Table S3). Therefore, RBM20 expression and activation of
RBM20-dependent splicing were induced by ATRA in all cellular
systems we tested.
Pharmacological Upregulation of RBM20 Leads to
Amelioration of Contractile and Calcium Handling
Defects
To determine whether ATRA-mediated correction of the splicing
defects improved the DCM phenotype, we measured calcium
handling and contractile function in human iPSC-CMs. Upon
ATRA treatment, we observed a dose-dependent reduction of
calcium upstroke time in iPSC-CMs DCM1 and DCM2 (Figures
4C and S4F). The homozygous engineered isogenic lines,
P633L and R634Q, produced a similar effect (Figures 4C and
S4F). No response was observed in the homozygous line
S635FS (Figures 4C and S4F). The S635FS mutation produces
a premature stop codon, resulting in presumably a functional
KO. Consistent with this interpretation, ATRA treatment in these
cells did not produce any beneficial effect on TTN and CAMK2D
splicing despite increasing RBM20 mRNA expression (Fig-
ure S4E). Therefore, the lack of rescue by ATRA in the homozy-
gous line S635FS suggests that the improved phenotype in the
other mutant lines was dependent on residual RBM20 activity.
Upon ATRA treatment of DCM1 and DCM2 iPSC-CMs, in parallel
with the reduction in calcium upstroke time, we observed a sig-nificant increase in contractility (Figures 4D and S4G). A slight in-
crease in contractility was observed in the homozygous engi-
neered isogenic lines, P633L and R634Q (although not
significant for these samples). Because no improvement was
observed in the KO iPSC-CMs, improvement in contractility
upon ATRA treatment appeared to be RBM20-dependent.
Although high doses of ATRA have been shown to be toxic to
some cells (Colleoni et al., 2011), our results suggest that cardi-
omyocytes tolerate this treatment regimen well because they
showed no signs of cell death, and the contractile function of
the RBM20 mutant cardiomyocytes improved relative to un-
treated controls.
DISCUSSION
We identified P633L as a pathogenic variant in RBM20 and eval-
uated its effect on cardiac-specific splicing. P633L mutant iPSC-
CMs showed aberrant splicing of previously described RBM20
targets, including TTN, CAMK2D, and RYR2 (Beraldi et al.,
2014; Guo et al., 2012; Maatz et al., 2014; Streckfuss-Bömeke
et al., 2017; Wyles et al., 2016), as well as defects in contractility
and calcium handling. At the molecular level, RBM20 mutations
have been reported to impair interactions with other spliceosomal
proteins (Maatz et al., 2014). Three lines of evidence have sug-
gested that RBM20 mutations act through a haploinsufficiency
mechanism. First, heart failure patients with high expression of
RBM20 have more correctly spliced targets whereas those with
lowRBM20 levels have an increased incidence of splicing defects
similar to those observed in patients with RBM20 mutations
(Maatz et al., 2014). Second, the amount of splicing of the TTN re-
porter in HEK293 cells has been shown to be RBM20 dose-
dependent (Guo et al., 2012). Third, in a genetic rat model, homo-
zygous RBM20 mutant rats have a more severe phenotype than
heterozygous rats (Maatz et al., 2014). Because all patients with
RBM20 mutations described to date are heterozygous (the other
allele being functional), we reasoned that transcriptional upregula-
tion of RBM20 would be beneficial. Similar approaches of gene
expression upregulation in haploinsufficiency have been benefi-
cial in disease models of Dravet syndrome (Hsiao et al., 2016)
and vascular stenosis (Zhang et al., 2012).
ATRA is an active metabolite of vitamin A. It acts as a
morphogen in early development during which it plays an essen-
tial role in the formation of the anteroposterior and dorsoventral
axes. During development, levels of ATRA that are too low or too
high are detrimental (Colleoni et al., 2011). After birth, vitamin A is
important for a number of physiological functions including
vision and immunity (Sommer, 2008). By analyzing the transcrip-
tomics data from embryonic stem cells treated with ATRA (Col-
leoni et al., 2011), we identified RBM20 as one of the genes up-
regulated upon ATRA treatment. We found that ATRA
upregulated RBM20 in iPSC-CMs and partially reverted the
splicing and contractile defect of the affected mutant iPSC-
CMs (Figure 4). This proof-of-concept suggests that the upregu-
lation of RBM20may be a viable therapeutic strategy for RBM20-
DCM. With respect to ATRA, the doses used here (5–10 mM) are
in range of the plasma concentrations for cancer chemotherapy
that have well-known side effects (Castaigne et al., 1993). None-
theless, RBM20-DCM is progressive with no specific treatmentCell Reports 32, 108117, September 8, 2020 5
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Figure 4. ATRA Reverts the DCM Phenotypes in iPSC-CM
(A) Relative gene expressionmeasured via qRT-PCR forRBM20 uponDMSOor 10 mMATRA treatment inWT- and patient-derived iPSC-CMs (n = 6–8). TATA-box
binding protein (TBP) is used as endogenous control and gene expression is plotted relative to their respective DMSOcontrols. Data are presented asmean ±SD.
(B) N2BA TTN isoform expression upon DMSO or 10 mMATRA treatment in WT- and patient-derived iPSC-CMs (n = 6–8). N2BA expression is normalized to total
TTN expression. The WT DMSO sample is set to 1. Data are presented as mean ± SD.
(C) Time-series-based analysis of calcium transients of RBM20 WT and mutant iPSC-CMs upon 10 mMATRA treatment. Upstroke time is the calcium influx time
(n = 18–24).
(D) Time-series-based analysis of contractile profiles of RBM20WT andmutant iPSC-CMs upon 10 mMATRA treatment (n = 12). AU, arbitrary unit; padj, adjusted
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ation should be given to clinically evaluate ATRA doses ranging
from levels recommended as a dietary supplement to potentially
toxic levels with appropriate monitoring for side effects.
ATRA did not improve calcium handling or contractility in the
homozygous S635FS mutant that lacks splicing activity (Figures
4C, 4D, and S4E–S4G). Therefore, we conclude that the benefi-
cial effect of ATRA was dependent on the presence of residual
RBM20 activity. We also found that ATRA partially ameliorated
the calcium handling defect of the homozygous mutant iPSC-
CMs (P633L and R634Q). We did not detect a significant
improvement of the contractility defect in the homozygous point
mutation lines, although a trend in this direction was visible. It is6 Cell Reports 32, 108117, September 8, 2020possible that the point mutants retain some residual function and
their upregulation contributes to the therapeutic effect of ATRA,
but this is insufficient to significantly ameliorate the contractility
defect in these homozygous mutant iPSC-CMs. To our knowl-
edge, only heterozygous pathogenic mutations in RBM20 have
been identified so far (Parikh et al., 2019). It is possible that ho-
mozygous and compound heterozygous pathogenic mutations
in RBM20 result in a more severe phenotype that would be
incompatible with postnatal life.
The precise mechanism by which ATRA upregulated RBM20
is uncertain. There is no consensus retinoic acid responsive
element in the promoter region of RBM20, suggesting that an in-
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tion sequencing (ChIP-seq) data revealed three cardiac-specific
transcription factors (GATA4, TB5, and NKX2-5) that bind to the
promoter region of RBM20 in murine cardiomyocytes (Luna-Zur-
ita et al., 2016). Regulation by these factors is consistent with the
RBM20 expression pattern in development (Beraldi et al., 2014)
and at the tissue level (Maatz et al., 2014). Indeed, GATA4 is
induced by ATRA as shown by others (Arceci et al., 1993) and
our own data (Figure S3E). By analyzing published microarray
data (GSE52317 from van Berlo et al. [2013]), we found that
RBM20 expression was reduced upon cardiac-specific GATA4
depletion in adult mouse hearts in vivo. Further studies are
necessary to investigate the effect of GATA4 loss-of-function
on RBM20-dependent splicing.
The use of genome editing technologies in combination with
in vitro differentiation of human iPSCs to evaluate pathogenicity
of variants identified in patients is emerging as a promising diag-
nostic tool. Its value has been shown recently in studies of vari-
ants related to channelopathy (Garg et al., 2018) and laminop-
athy (Lee et al., 2019). Our data use this technology to assess
the pathogenicity of a DCM-causing missense mutation in
RBM20.
In our system, several genes’ splicing is affected by mutations
in RBM20. These findings agree with and extend previous work.
Determining the splicing targets of RBM20 is non-trivial. A
conserved set of 31 genes were inferred from RNA-seq data
on both human and rat cells (Guo et al., 2012) while 18 direct
RBM20-bound genes were identified by HITS-CLIP on rat cardi-
omyocytes (Maatz et al., 2014), with only four genes, including
TTN,CAMK2D, LDB3, and SORBS1, overlapping both datasets.
Among these four genes, we observe mis-splicing of TTN and
CAMK2D and observemis-splicing of the same exons previously
reported (Maatz et al., 2014; van den Hoogenhof et al., 2018).
Calcium mishandling in RBM20 mutant cardiomyocytes has
been attributed to the function of RBM20 as a splicing-regulator
of several calcium handling genes including CAMK2D and CAC-
NA1C (Maatz et al., 2014; Streckfuss-Bömeke et al., 2017; van
den Hoogenhof et al., 2018; Wyles et al., 2016). We (Figures 2A
and S2D), and others (Streckfuss-Bömeke et al., 2017; Wyles
et al., 2016), found that RBM20 regulated the splicing of a small
exon (24 bp) in RyR2, which plays a major role in the release of
calcium from the sarcoplasmic reticulum (SR) and triggers car-
diac contraction. This exon was shown to regulate subcellular
localization of the protein (George et al., 2007). Despite aberrant
splicing of calcium handling proteins, the physiological conse-
quences of RBM20 mutation on iPSC-CM contractility has not
been detected. We confirmed aberrant splicing of RYR2 (Fig-
ureS2D) andwere able to detect reduced contractility (Figure 2C)
and delayed calcium upstroke (Figure 2D). We attribute our abil-
ity to detect the pathophysiological consequences to (1) isogenic
controls that match the mutant cell and hence increase sensi-
tivity and specificity of the effects, and (2) the increased reliance
on sarcoplasmic reticulum Ca2+ in our iPSC-CMs that were
cultured in the presence of oxidative substrates, which increases
sarcoplasmic reticulum Ca2+ load relative to iPSC-CMs main-
tained under glycolytic conditions (Feyen et al., 2020) (STAR
Methods). Aberrant regulation of CAMK2D, RYR2, and cytosolic
calcium play a central role in susceptibility to ventriculararrhythmia (Bers, 2014). Given that ATRA had a normalizing ef-
fect on CAMK2D as well as on calcium dynamics, it is tempting
to speculate that it might also normalize the arrhythmogenic pro-
pensity of RBM20 mutant DCM.
In summary, the CRISPR-engineered iPSC-CMs model of
RBM20-deficient DCM revealed molecular and cellular pheno-
types relevant to DCM pathogenesis, including defective
contractility and calcium transients. We found that ATRA
increased RBM20 gene expression. Moreover, treatment with
ATRA partially reverted the in vitro DCM phenotypes. Our data
support upregulation of endogenous RBM20 as a therapeutic
strategy for RBM20-deficient-DCM.
Limitations of Study
RBM20mutations result in an arrhythmogenic form of DCM. We
have not evaluated the P633L variant iPSC-CMs for proarrhyth-
mic potential, but noted both the R634Q and P633L iPSC-CMs
have splicing alterations that are predicted to result in altered
CAMK2D andRYR2proteins (Figure 2A). These proteinsmediate
a positive feedback circuit involved in ventricular arrhythmia
(Bers, 2014), and CAMK2D splicing is reverted by ATRA (Figures
S4C and S4D). It will be interesting to explore if P633L RBM20
mutant iPSC-CMs display proarrhythmic calcium features as
noted previously for the R634Q variant (Wyles et al., 2016) and
whether these are reverted by ATRA. In addition, our data indi-
cate that the mechanism of ATRA is transcriptional upregulation
of RBM20 leading to an increase in the protein expression (Fig-
ures 3, 4A, S3C, and S3D) that compensates for a functional
deficit. How this upregulation occurs, and whether additional
mechanisms can be targeted to boost RBM20 expression or ac-
tivity, is the focus of ongoing studies.
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Ulmer, B., Zhang, H., Briganti, F., Schweizer, M., Hegyi, B., et al. (2020). Meta-
bolic Maturation Media Improve Physiological Function of Human iPSC-
Derived Cardiomyocytes. Cell Rep. 32, 107925.
Garg, P., Oikonomopoulos, A., Chen, H., Li, Y., Lam, C.K., Sallam, K., Perez,
M., Lux, R.L., Sanguinetti, M.C., and Wu, J.C. (2018). Genome Editing of
Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.
J. Am. Coll. Cardiol. 72, 62–75.
George, C.H., Rogers, S.A., Bertrand, B.M.A., Tunwell, R.E.A., Thomas, N.L.,
Steele, D.S., Cox, E.V., Pepper, C., Hazeel, C.J., Claycomb,W.C., and Lai, F.A.
(2007). Alternative splicing of ryanodine receptors modulates cardiomyocyte
Ca2+ signaling and susceptibility to apoptosis. Circ. Res. 100, 874–883.
Guo, W., Schafer, S., Greaser, M.L., Radke, M.H., Liss, M., Govindarajan, T.,
Maatz, H., Schulz, H., Li, S., Parrish, A.M., et al. (2012). RBM20, a gene for he-
reditary cardiomyopathy, regulates titin splicing. Nat. Med. 18, 766–773.
Hershberger, R.E., Morales, A., and Siegfried, J.D. (2010). Clinical and genetic
issues in dilated cardiomyopathy: a review for genetics professionals. Genet.
Med. 12, 655–667.
Hershberger, R.E., Hedges, D.J., and Morales, A. (2013). Dilated cardiomyop-
athy: the complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 10,
531–547.
Hey, T.M., Rasmussen, T.B., Madsen, T., Aagaard, M.M., Harbo, M., Møl-
gaard, H., Møller, J.E., Eiskjær, H., and Mogensen, J. (2019). Pathogenic
RBM20-Variants Are Associated With a Severe Disease Expression in Male
Patients With Dilated Cardiomyopathy. Circ. Heart Fail. 12, e005700.
Hsiao, J., Yuan, T.Y., Tsai, M.S., Lu, C.Y., Lin, Y.C., Lee, M.L., Lin, S.W.,
Chang, F.C., Liu Pimentel, H., Olive, C., et al. (2016). Upregulation of Haploin-
sufficient Gene Expression in the Brain by Targeting a Long Non-coding RNA
Improves Seizure Phenotype in a Model of Dravet Syndrome. EBioMedicine 9,
257–277.
Janin, A., Bessière, F., Chauveau, S., Chevalier, P., and Millat, G. (2018). First
identification of homozygous truncating CSRP3 variants in two unrelated
cases with hypertrophic cardiomyopathy. Gene 676, 110–116.
Japp, A.G., Gulati, A., Cook, S.A., Cowie, M.R., and Prasad, S.K. (2016). The





Cell Reports c'Ce =>ress Kinnamon, D.D., Morales, A., Bowen, D.J., Burke, W., and Hershberger, R.E.;
DCM Consortium* (2017). Toward Genetics-Driven Early Intervention in
Dilated Cardiomyopathy: Design and Implementation of the DCM Precision
Medicine Study. Circ. Cardiovasc. Genet. 10, e001826.
Lee, J., Termglinchan, V., Diecke, S., Itzhaki, I., Lam, C.K., Garg, P., Lau, E.,
Greenhaw, M., Seeger, T., Wu, H., et al. (2019). Activation of PDGF pathway
links LMNA mutation to dilated cardiomyopathy. Nature 572, 335–340.
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Bur-
rows-Wheeler transform. Bioinformatics 25, 1754–1760.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Sub-
group (2009). The Sequence Alignment/Map format and SAMtools. Bioinfor-
matics 25, 2078–2079.
Li, D., Morales, A., Gonzalez-Quintana, J., Norton, N., Siegfried, J.D., Hof-
meyer, M., and Hershberger, R.E. (2010). Identification of novel mutations in
RBM20 in patients with dilated cardiomyopathy. Clin. Transl. Sci. 3, 90–97.
Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general
purpose program for assigning sequence reads to genomic features. Bioinfor-
matics 30, 923–930.
Liss, M., Radke, M.H., Eckhard, J., Neuenschwander, M., Dauksaite, V., von
Kries, J.P., and Gotthardt, M. (2018). Drug discovery with an RBM20 depen-
dent titin splice reporter identifies cardenolides as lead structures to improve
cardiac filling. PLoS ONE 13, e0198492.
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25, 402–408.
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold
change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
Luna-Zurita, L., Stirnimann, C.U., Glatt, S., Kaynak, B.L., Thomas, S., Baudin,
F., Samee, M.A., He, D., Small, E.M., Mileikovsky, M., et al. (2016). Complex
Interdependence Regulates Heterotypic Transcription Factor Distribution
and Coordinates Cardiogenesis. Cell 164, 999–1014.
Lund, L.H., Khush, K.K., Cherikh, W.S., Goldfarb, S., Kucheryavaya, A.Y., Lev-
vey, B.J., Meiser, B., Rossano, J.W., Chambers, D.C., Yusen, R.D., and Steh-
lik, J.; International Society for Heart and Lung Transplantation (2017). The
Registry of the International Society for Heart and Lung Transplantation: Thir-
ty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft
ischemic time. J. Heart Lung Transplant. 36, 1037–1046.
Maatz, H., Jens, M., Liss, M., Schafer, S., Heinig, M., Kirchner, M., Adami, E.,
Rintisch, C., Dauksaite, V., Radke, M.H., et al. (2014). RNA-binding protein
RBM20 represses splicing to orchestrate cardiac pre-mRNA processing.
J. Clin. Invest. 124, 3419–3430.
Marks, A.R. (2003). Calcium and the heart: a question of life and death. J. Clin.
Invest. 111, 597–600.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky,
A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010).
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res. 20, 1297–1303.
McNally, E.M., and Mestroni, L. (2017). Dilated Cardiomyopathy: Genetic De-
terminants and Mechanisms. Circ. Res. 121, 731–748.
Miller, J.N., and Pearce, D.A. (2014). Nonsense-mediated decay in genetic dis-
ease: friend or foe? Mutat. Res. Rev. Mutat. Res. 762, 52–64.
Parikh, V.N., Caleshu, C., Reuter, C., Lazzeroni, L.C., Ingles, J., Garcia, J.,
McCaleb, K., Adesiyun, T., Sedaghat-Hamedani, F., Kumar, S., et al. (2019).
Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Car-
diomyopathy. Circ. Heart Fail. 12, e005371.
Patwardhan, A., Harris, J., Leng, N., Bartha, G., Church, D.M., Luo, S., Hau-
denschild, C., Pratt, M., Zook, J., Salit, M., et al. (2015). Achieving high-sensi-
tivity for clinical applications using augmented exome sequencing. Genome
Med. 7, 71.Petryszak, R., Burdett, T., Fiorelli, B., Fonseca, N.A., Gonzalez-Porta, M.,
Hastings, E., Huber, W., Jupp, S., Keays, M., Kryvych, N., et al. (2014). Expres-
sion Atlas update–a database of gene and transcript expression frommicroar-
ray- and sequencing-based functional genomics experiments. Nucleic Acids
Res. 42, D926–D932.
Picelli, S., Faridani, O.R., Björklund, A.K., Winberg, G., Sagasser, S., and
Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-
seq2. Nat. Protoc. 9, 171–181.
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013).
Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–
2308.
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celik, C., Perrot, A., Sossalla, S., Haas, J., et al. (2017). Severe DCMphenotype
of patient harboring RBM20 mutation S635A can be modeled by patient-spe-
cific induced pluripotent stem cell-derived cardiomyocytes. J. Mol. Cell. Car-
diol. 113, 9–21.
van Berlo, J.H., Aronow, B.J., and Molkentin, J.D. (2013). Parsing the roles of
the transcription factors GATA-4 and GATA-6 in the adult cardiac hypertrophic
response. PLoS ONE 8, e84591.
van den Hoogenhof, M.M.G., Beqqali, A., Amin, A.S., van der Made, I., Aufiero,
S., Khan, M.A.F., Schumacher, C.A., Jansweijer, J.A., van Spaendonck-
Zwarts, K.Y., Remme, C.A., et al. (2018). RBM20Mutations Induce an Arrhyth-
mogenic Dilated Cardiomyopathy Related to Disturbed Calcium Handling. Cir-
culation 138, 1330–1342.
Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation
of genetic variants from high-throughput sequencing data. Nucleic Acids Res.
38, e164.
Wilcox, J.E., and Hershberger, R.E. (2018). Genetic cardiomyopathies. Curr.
Opin. Cardiol. 33, 354–362.
Wyles, S.P., Li, X., Hrstka, S.C., Reyes, S., Oommen, S., Beraldi, R., Edwards,
J., Terzic, A., Olson, T.M., and Nelson, T.J. (2016). Modeling structural and
functional deficiencies of RBM20 familial dilated cardiomyopathy using human
induced pluripotent stem cells. Hum. Mol. Genet. 25, 254–265.
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Jr., Drazner,
M.H., Fonarow, G.C., Geraci, S.A., Horwich, T., Januzzi, J.L., et al. (2013).
2013 ACCF/AHA guideline for themanagement of heart failure: executive sum-
mary: a report of the American College of Cardiology Foundation/American
Heart Association Task Force on practice guidelines. Circulation 128, 1810–
1852.
Zhang, P., Huang, A., Morales-Ruiz, M., Starcher, B.C., Huang, Y., Sessa,
W.C., Niklason, L.E., and Giordano, F.J. (2012). Engineered zinc-finger pro-
teins can compensate genetic haploinsufficiency by transcriptional activation
of the wild-type allele: application to Willams-Beuren syndrome and supra-




t'Ce =>ress Cell Reports STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
rabbit polyclonal anti-RBM20 Guo et al., 2012 N/A
anti-aTubulin Calbiochem DM1A
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html/DEXSeq.html
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Lars




Cell Reports c'Ce =>ress Material Availability
Further information and requests for resources should be directed to andwill be fulfilled by the Lead Contact. Unique reagents gener-
ated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.
Data and Code Availability
The datasets generated during this study are available at the Sequence Read Archive (SRA) Database with accession number
PRJNA579336.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Human samples
iPSC lines from the proband and his father (DCM1 and DCM2 respectively) were derived at the Stanford Stem Cell Core under the
IRB-30064 protocol from blood cells using the Thermo Fisher CytoTune2.0 kit (A16517). Participants gave written informed consent.
A control iPSC line was obtained from the Stanford Cardiovascular Institute Biobank.
Cardiomyocyte differentiation and treatment
iPSCs were differentiated into cardiomyocytes as a monolayer and through the modulation of Wnt signaling as previously described
(Burridge et al., 2015). Briefly, iPSCs were plated at low density on matrigel coated plates to achieve 70%–80% confluency after
4 days (Day 0 of differentiation) when differentiation was induced with RPMI supplemented with 1XB27 Minus Insulin (Life Technol-
ogies 0050129SA) and 6 mMCHIR99021 (TOCRIS 4953). On Day 3, media was replaced with RPMI supplemented with 1XB27Minus
Insulin and 5 mM IWR (Selleckchem S7086). On Day 5, media was replaced with RPMI supplemented with 1XB27Minus Insulin. From
Day 7 to day 11, cells were kept in RPMI supplemented with 1XB27. To increase cardiomyocyte purity, cells were cultured in RPMI
without glucose for three days. On day 16, the iPSC-CMs were dissociated with TrypLE 10x and seeded in 6-well Matrigel coated
plates at a density of 3x106 per well in RPMI with 1XB27 containing 10% KOSR and ROCK inhibitor Y-27632 (Tocris, Bristol, UK)
(replating media). After 2 days, cells were cultured in RPMI with 1XB27 without glucose for 3 days prior to switching to 3ml of a meta-
bolism-based maturation media (Feyen et al., 2020).
All-trans retinoic acid (ATRA) was purchased from Sigma (R 2625) and dissolved in DMSO according to manufacturer’s instruc-
tions. For gene expression and splicing analysis, cells were treated for 48h with either ATRA or the same volume of DMSO
(0.01% v/v). For contractility and calcium assays, cells were treated for 72 hours to allow enough time for the targets to be translated
into proteins and accumulate to a significant level. All ATRA handling was performed in the dark and cell culture plates were wrapped
in aluminum foil to protect ATRA from light exposure.
HEK cells maintenance and transfection
Human embryonic kidney (HEK293.EBNA) cells (Life Technologies GmbH, Darmstadt, Germany) were maintained in high glucose
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (Sigma-Aldrich Chemie GmbH, Munich,
Germany [F7524, Lot#124M3337]) and 1% penicillin/streptomycin 10,000 U/mL (GIBCO by Life Technologies GmbH, Darmstadt,
Germany).
For transfection of HEK cells, 25000 cells/well were seeded on 96-well Nunc F96 MicroWell plates (Life Technologies GmbH,
Darmstadt, Germany) and reverse transfected with a total of 60 ng of plasmid DNA per well of which 1 ng was splicing reporter,
1 ng was RBM20 or control plasmid (pcDNA3.1), and 58 ng empty vector pBSSK. To deliver plasmid DNAwe used the 160 kDa linear
polyethylenimine (Polysciences Europe GmbH, Hirschberg, Germany) at a 1:2.2 ratio (DNA:PEI160). Cells were incubated for 60 h at
37C in the presence of 5% CO2.
C2C12 maintenance
C2C12 cells (Sigma Aldrich, Munich) were maintained in high glucose Dulbecco’s modified eagle medium (DMEM) supplemented
with 10% fetal bovine serum (Sigma-Aldrich Chemie GmbH, Munich, Germany [F7524, Lot#124M3337]) and 1% penicillin/strepto-
mycin 10,000 U/mL (GIBCO by Life Technologies GmbH, Darmstadt, Germany).
METHOD DETAILS
Linkage analysis in a family with familial DCM
Exome sequencing for the proband (III;4), his father (II;4), his mother (II;3) and his aunt (II;6) was performed on blood cells. DNA was
isolated using Gentra Puregene Kits (QIAGEN) following manufacturer’s instructions. Sequencing was performed at Personalis using
the ACE Clinical Exome Test, which includes sequencing of selected non-coding regions (Patwardhan et al., 2015). Paired-end
sequencing with 2x100 base pair reads was used and an average coverage of 60x was achieved (Figure S1A). The reads were map-
ped to the human genome referenceGRCh37. Single Nucleotide Variants (SNVs) and INDELswere called and filtered usingGATK (v3)




t'Ce =>ress Cell Reports Variants identified as being in common between III;4, II;4, II;6 and absent in II;3, were first filtered by their frequency in the 1000
genome project, with those whose frequency is higher than 5% excluded. Next, the remaining variants were filtered according to
their effects on protein sequences, removing those locating in intergenic, intronic, UTR regions, or having synonymous changes.
Third, only the variants in the genes related to heart development or heart diseases (101 genes) were retained. Fourth, variants
were checked manually in the raw sequence trace files to remove false positive calls. Finally, the remaining variants were checked
against the ClinVar database to exclude those annotated as benign, likely benign, or variant of uncertain significance.
Independent clinical sequence validation was carried out on the father (II;4). Genomic DNA was tested by Next-Generation
Sequencing (NGS) using a customdesign, based on a SeqCap EZSolution-Based Enrichment strategy (RocheNimbleGen,Madison,
Wisconsin). Targeted sequencing capture probes were custom designed by Roche NimbleGen. The panel was designed to identify
disease-causingmutations in 48 cardiomyopathy-causing genes (Janin et al., 2018). Target regions included coding exons (padding:
30 bp), as well as 50- and 30-UTR regions. Libraries were constructed with the Kapa Library Preparation Kit for Illumina platforms
(Kapa Biosystems, London, UK) according to the manufacturer’s instructions and further sequenced on a Next-Seq500 sequencer
using the NextSeq500 Mid Output Kit v2 (300 cycles) chemistry (Illumina, San Diego, California). In silico analysis was performed us-
ing a personalized Sophia Genetics pipeline optimized for both single nucleotide polymorphism (SNP)/indels and copy number vari-
ation (CNV) detection (Chanavat et al., 2016).
Genome editing
Single guide RNAs were designed using the Feng Zhang lab’s CRISPR Design tool (http://zlab.bio/guide-design-resources). Two
complementary oligonucleotides making up the gRNA construct were ordered separately (Table S4), annealed in T4 ligation buffer
(NEB), and phosphorylated with T4 PNK (NEB). Annealed and phosphorylated oligonucleotides were cloned into the BbsI sites of the
pSpCas9(BB)-2A-GFP plasmid and transformed into STBL3 E. coli cells. The sequence of the gRNA cloneswas confirmed by Sanger
sequencing.
Human iPSCs were plated into Matrigel coated 6-well plates one day before transfection at low density in Essential 8 (E8) media.
On the day of transfection, media was changed to E8 supplemented with Rock inhibitor (Tocris Cat. No. 1254). Cells were transfected
with Lipofectamine 3000 following manufacturer’s instructions. CRISPR/Cas9 vector (1m, pSpCas9(BB)-2A-GFP) and 4 mg of single-
stranded DNA (ssDNA) donor (Table S4) or 3mg of targeting vector were used for each well of a 6-well plate. GFP+ cells were isolated
36-48 hours after transfection using a FACSAria IIu (DB Biosciences) flow cytometer with a 100-mm nozzle. Cells were plated at a
density of 2-3x103 cells/well in a 6-well plate in E8 media supplemented with Rock inhibitor. Cells were maintained in E8 media sup-
plemented with Rock inhibitor for the first 3 days and were cultured in regular E8 media until the colonies reached a size of0.5 mm.
Individual iPSC clones were isolated with the assistance of a stereomicroscope located inside a cell culture cabinet and each clone
was re-plated in awell of a 24-well plate in E8 supplemented with Rock inhibitor. A few cells for each clonewere resuspended in 20 mL
media and used for genomic DNA isolation with 0.5 mL of DNA Release Additive in 20 mL Dilution Buffer (Phire Animal Tissue Direct
PCR Kit (Thermo Fisher)). Finally, 2 mL of themix was used for direct PCR amplification of the target genomic region using PrimeSTAR
GXL DNA Polymerase (Clontech).
To confirm that homozygous edits did not result from loss of one of the two alleles, we examined the parental line and found it has
three heterozygous variants in the 30UTR of RBM20 at positions Chr10:110836524, Chr10:110837082, Chr10:110837531. We
analyzed the RNaseq data and found that all three heterozygous variants are present and expressed in all the edited lines.
The top 3 predicted off-targets of the guide RNA were amplified and analyzed via Sanger sequencing to exclude the presence of
unwanted editing (data not shown).
For the mCherry-RBM20 knock-in, the mCherry ORF was amplified from pREST-B mCherry using primers mCherry_Fwand
mCherryRV (Table S4), and homology recombination arms form human genomic DNAwith primers RBM20_RA_FW, RBM20_RA_RV,
RBM20_LA_FW, RBM20_LA_RV (Table S4). pUC19 was used as backbone and amplified with primers pUC_FW and pUC_RV (Table
S4). The targeting vector was obtained via Gibson assembly.
Splicing Reporter Assay
The reporter assay has previously been described (Guo et al., 2012). We transfect a plasmid expressing wild-type RBM20
(pcDNA3.1RBM20) or empty vector (pcDNA3.1) for reference and compare treatment with compound versus vehicle. Compounds
were applied to the microtiter plate in a final volume of 20 mL (1:19) in complete growth medium with 80 mL cell/transfection mix
seeded on at the indicated concentrations at a final DMSO concentration of 1%. Luciferase activity was measured 60 hours post-
transfection using the Dual-Luciferase Reporter Assay System (Promega GmbH, Mannheim, Germany) on an Infinite M200
Pro (TECAN, Maennedorf, Switzerland) plate reader.
Protein analysis
C2C12 cells were harvested using trypsin/EDTA 0.25% for 2min at 37Cwith subsequent downstream processing or snap freezing in
liquid nitrogen. For protein extraction, samples were suspended in RIPA buffer (50 mM Tris pH 8.0, 150 mMNaCl, 1%NP-40, 0.25%
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for 20 min at 4C using BCA assay (Life Technologies GmbH, Darmstadt, Germany [23225]). Samples were kept cool at all times.
For quantitation of proteins we used a partially automated Simple Western System (WES), based on capillary electrophoresis with
reagents provided by the manufacturer (WES, ProteinSimple, San Jose, CA). They include biotinylated molecular weight marker,
streptavidin–HRP fluorescent standards, luminol-S, hydrogen peroxide, sample buffer, DTT, stacking matrix, separation matrix,
running buffer, wash buffer, and matrix removal buffer, secondary antibodies, antibody diluent, and capillaries, which we used ac-
cording to the manufacturer’s recommendations. The stock samples were adjusted to working stocks of 2 mg/ml and diluted 10-fold
using the 0.1X sample buffer and 5X master mix (200 mM DTT, 53 sample buffer, 53 fluorescent standards). Samples were dena-
tured at 95C for 5 min., and loaded with biotinylated ladder, chemiluminiscent substrate, primary antibodies (rabbit polyclonal anti-
RBM2015 and anti-aTubulin DM1A (Calbiochem)) and secondary antibodies onto the designated wells in a pre-microplate (Protein-
Simple) prefilled with separation gel. Automated electrophoresis (375 V, 25 min, Antibody diluent time 5 min, primary & secondary
antibody time 30 min) and immunodetection were performed following manufacturer’s instructions. For data analysis, we used
the Compass Software (ProteinSimple). The area under the curve of the protein of interest was divided by (normalized) the area under
the curve of the loading control protein (a-Tubulin) peak. Representative (‘‘virtual blot’’) electrophoretic images were automatically
generated by the Compass Software (ProteinSimple).
RNA sequencing
Two RNA sequencing experiments were performed. The first RNA-seq experiment was done to identify the splicing effect of the
RBM20 mutations on two-month-old iPSC-CMs of five genotypes (P663L, R634Q, S635FS, WT, and WT-NC) each with three rep-
licates from independent differentiations. A second experiment was performed to test and validate the effect of ATRA on two-month-
old WT, DCM1, and S635FS iPSC-CM of four replicates from three independent differentiations. RNA was purified using TRizol
extraction and isopropanol precipitation. For the first experiment total RNA (2-10 ng) was reverse transcribed to generate full-length
complementary DNA (cDNA) using SmartSeq2 (Picelli et al., 2014). Then, 100-200 pg of full-length cDNA was tagmented using Illu-
mina’s Nextera XT kit to generate fragments with a median length of 500 bp for the addition of the sequencing index adapters as
described by the manufacturer’s protocol. Multiple samples with different sequencing indexes were pooled and sequenced on mul-
tiple Illumina HiSeq lanes at an average depth of 100 million reads per sample. For the second experiment, after DNAase and deple-
tion of ribosomal RNA treatment, libraries were prepared using the Trueseq protocol. Multiple samples with different sequencing in-
dexes were pooled and sequenced on multiple Illumina Nextseq runs with 75 pair end reads at an average depth of 60 million reads
per sample for the second experiment. RNA-Seq reads were mapped to GRCh38 using STAR v2.5.1b. Gene expression levels were
determined with featureCounts v1.6.0 (Liao et al., 2014). For each exon, inclusive and exclusive reads were defined. Inclusive reads
are reads that include the exon of interest. Exclusive reads are reads that include both the upstreamand downstream exon but not the
exon of interest. Inclusive and exclusive readswere counted directly from theBAMfiles using a custom script. Percentage of Spliced-
In (PSI) is the ratio of inclusive reads to the sum of inclusive and exclusive reads. We identified differentially expressed genes using
DESeq2 v1.22.0 with the effect from genotype or differentiation regressed out (e.g., Expression Condition + Genotype in the first
experiment, or Expression Treatment + Differentiation in the second experiment). Adjusted p values were calculated using Benja-
mini &Hochbergmethod.We detected alternative splicing with DEXSeq v1.16.10 (Anders et al., 2012). Themean of the counts across
all samples for each exon was extracted from DEXSeq. Exons with an average of less than 64 (26) counts were excluded. We consid-
ered an exon as alternatively spliced when DEXSeq padj (adjusted p value, Benjamini & Hochberg) was < 0.05 and the difference in
themedian of PSI values was > 0.1. We identified 20 significant differentially spliced genes with one exon each. Two exceptions were
TTN and CAMK2D. For TTNwe only reported the most significant exon because several exons were affected, all being preferentially
included in the RBM20 mutant lines. For CAMK2D two mutually exclusive exons were affected: one is preferentially included in the
WT iPSC-CMs (CAMK2D-E14 in Figures 2A and S2B) and one is preferentially included in the RBM20mutant iPSC-CMs (CAMK2D-
E15 in Figures 2A and S2B).
qRT-PCR
To analyze transcript expression in C2C12 cells total RNA was extracted from cultured cells using ReliaPrep RNA Tissue Miniprep
System (Promega, Madison WI, USA) according to the manufacturer’s instructions. 2 mg of total RNA were reverse transcribed using
the High-Capacity RNA-to-cDNA Kit (Life Technologies GmbH, Darmstadt, Germany). Quantitative RT-PCR was performed using
SYBRGreen master mix (Applied Biosystems by Thermo Fisher Scientific Inc., USA) on a 7900 HT RT-cycler (Applied Biosystems
by Thermo Fisher Scientific, Inc., USA). To quantify gene expression, we used the DDCT method. PSI values were calculated as a
ratio of unspliced to spliced reporter transcript. Primer sets are previously published (Liss et al., 2018). N = 3 samples were used.
Comparison between groups used Dunnett’s post-test against CTRL.
To analyze transcript isoforms in iPSC-CMs, two-month-old cardiomyocytes from 3 independent differentiation experiments were
collected, RNA was purified using TRizol extraction and isopropanol precipitation, and reverse transcription was performed on
500 ng of total RNA using SuperScript VILO cDNA Synthesis Kit (Life Technologies), following manufacturer’s instructions. PCR
was performed using PrimeSTAR GXL DNA Polymerase from Takara Bio. Quantitative RT-PCR (qRT-PCR) was performed with Bio-
rad SYBR Green Master Mix. Primer sequences are provided in Table S4. Relative transcript expression to control was calculated
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centering batch correction was applied. Adjusted p values were calculated with the FDR method.
Image acquisition
For imaging experiments, cells were dissociated and plated onto Matrigel-coated 384-well tissue culture plates (Greiner Bio-One) at
a density of 2x104 cells/well. Cells were allowed to recover for 4 days changing media every second day. All cell manipulations were
conducted in a cell culture cabinet on a 37C dry heat block and all the solutions were pre-warmed to 37C to prevent temperature
fluctuations. Cells were washed 4 times with Fluorobrite (Thermo Fisher A1896701). For contractility analysis, cells were loaded for
15 min with 4 mg/ml of Hoechst 33258 (H3569, Life Technologies) and 10 mg/ml of wheat germ agglutinin–Alexa Fluor 488 conjugate
(W11261, Life Technologies) in Fluorobrite. Time series images were acquired automatically using the IC200 KIC instrument (Vala
Sciences, California, USA) at an acquisition frequency of 100 Hz for a duration of 10 s, with excitation wavelength of 485/20 nm
and emission filter 525/30 nm using a 0.75 NA 20x Nikon Apo VC objective. A single image of the Hoechst stain was acquired after
the time series. For each condition and cell line 6 wells from each of 2 independent differentiations were analyzed (n = 12).
For calcium analysis, cells were loaded for 20 min with 4 mg/ml of Hoechst 33258 and 2.7 mM Fluo-4NW (Thermo Fisher F36206) in
Fluorobrite. After fluorophore loading, cells were washed 4 more times before image acquisition. Time series images were acquired
automatically using the IC200 KIC instrument (Vala Sciences, California, USA) at an acquisition frequency of 100 Hz for a duration of
10 s, with excitation wavelength of 485/20 nm and emission filter 525/30 nm using a 0.75 NA 20x Nikon Apo VC objective. A single
image of the Hoechst stain was acquired after the time series. For each condition and each cell line, 6 wells from each of 3 indepen-
dent differentiations were analyzed (n = 18).
Image analysis and calculation of physiological parameters
Image analysis and physiological parameter calculation was conducted using commercially available Cyteseer (Vala Sciences) (Cer-
ignoli et al., 2012). Contractility analysis was performed using a custom particle image velocity algorithm. Contractility is quantified as
the relative change in area of the beating cells, given by the divergence of the measured deformation field, and reported as the peak
divergence amplitude (Serrano et al., 2018; Sharma et al., 2017). Data tables were analyzed using R. Comparisons between multiple
groups were evaluated for significance using a two-way ANOVA, followed by multiple comparison of means using Tukey’s test.
QUANTIFICATION AND STATISTICAL ANALYSIS
Error bars represent standard deviations unless otherwise specified. For pairwise comparison we used the Student’s t test or the
Wilcox test as appropriate. To compare multiple groups, we used two-way ANOVA to account for batch effect, followed by multiple
comparison of means using Tukey’s test. Further details are provided in the context of each specific assay in the relevant section of
the Method Details.e5 Cell Reports 32, 108117, September 8, 2020
